Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Research article

Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research

Authors: Jennifer Huberty, Ryan Eckert, Amylou Dueck, Heidi Kosiorek, Linda Larkey, Krisstina Gowin, Ruben Mesa

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

Myeloproliferative neoplasm (MPN) patients suffer from significant symptoms, inflammation and reduced quality of life. Yoga improves these outcomes in other cancers, but this hasn’t been demonstrated in MPNs. The purpose of this study was to: (1) explore the limited efficacy (does the program show promise of success) of a 12-week online yoga intervention among MPN patients on symptom burden and quality of life and (2) determine feasibility (practicality: to what extent a measure can be carried out) of remotely collecting inflammatory biomarkers.

Methods

Patients were recruited nationally and randomized to online yoga (60 min/week of yoga) or wait-list control (asked to maintain normal activity). Weekly yoga minutes were collected with Clicky (online web analytics tool) and self-report. Those in online yoga completed a blood draw at baseline and week 12 to assess inflammation (interleukin-6, tumor necrosis factor-alpha [TNF-α]). All participants completed questionnaires assessing depression, anxiety, fatigue, pain, sleep disturbance, sexual function, total symptom burden, global health, and quality of life at baseline, week seven, 12, and 16. Change from baseline at each time point was computed by group and effect sizes were calculated. Pre-post intervention change in inflammation for the yoga group was compared by t-test.

Results

Sixty-two MPN patients enrolled and 48 completed the intervention (online yoga = 27; control group = 21). Yoga participation averaged 40.8 min/week via Clicky and 56.1 min/week via self-report. Small/moderate effect sizes were generated from the yoga intervention for sleep disturbance (d = − 0.26 to − 0.61), pain intensity (d = − 0.34 to − 0.51), anxiety (d = − 0.27 to − 0.37), and depression (d = − 0.53 to − 0.78). A total of 92.6 and 70.4% of online yoga participants completed the blood draw at baseline and week 12, respectively, and there was a decrease in TNF-α from baseline to week 12 (− 1.3 ± 1.5 pg/ml).

Conclusions

Online yoga demonstrated small effects on sleep, pain, and anxiety as well as a moderate effect on depression. Remote blood draw procedures are feasible and the effect size of the intervention on TNF-α was large. Future fully powered randomized controlled trials are needed to test for efficacy.

Trial registration

This trial was retrospectively registered with clinicaltrials.gov (ID: NCT03503838) on 4/19/2018.
Literature
1.
go back to reference Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.CrossRef Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.CrossRef
2.
go back to reference Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.CrossRef Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.CrossRef
3.
go back to reference Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–10.CrossRef Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–10.CrossRef
4.
go back to reference Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97.CrossRef Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97.CrossRef
5.
go back to reference Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88–99.CrossRef Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88–99.CrossRef
6.
go back to reference Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses. J Hematol Oncol. 2017;10(1):156.CrossRef Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses. J Hematol Oncol. 2017;10(1):156.CrossRef
7.
go back to reference Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs). Cancer. 2007;109(1):68–76.CrossRef Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs). Cancer. 2007;109(1):68–76.CrossRef
8.
go back to reference Gowin KL, Langlais BT, Kosiorek HE, et al. Sleep and psychiatric disturbance in chronic Philadelphia negative myeloproliferative neoplasms. Blood. 2017;130:4189. Gowin KL, Langlais BT, Kosiorek HE, et al. Sleep and psychiatric disturbance in chronic Philadelphia negative myeloproliferative neoplasms. Blood. 2017;130:4189.
9.
go back to reference Padrnos L, Scherber RM, Langlais BT, et al. Myeloproliferative neoplasms and depressive symptoms, diagnosis, and associations. Blood. 2017;130:2161.CrossRef Padrnos L, Scherber RM, Langlais BT, et al. Myeloproliferative neoplasms and depressive symptoms, diagnosis, and associations. Blood. 2017;130:2161.CrossRef
10.
go back to reference Buffart LM, Van Uffelen JG, Riphagen II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2012;12(1):559.CrossRef Buffart LM, Van Uffelen JG, Riphagen II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2012;12(1):559.CrossRef
11.
go back to reference Cote A, Daneault S. Effect of yoga on patients with cancer: our current understanding. Can Fam Phys. 2012;58(9):e475–9. Cote A, Daneault S. Effect of yoga on patients with cancer: our current understanding. Can Fam Phys. 2012;58(9):e475–9.
12.
go back to reference Harder H, Parlour L, Jenkins V. Randomised controlled trials of yoga interventions for women with breast cancer: a systematic literature review. Suppot Care Cancer. 2012;20(12):3055–64.CrossRef Harder H, Parlour L, Jenkins V. Randomised controlled trials of yoga interventions for women with breast cancer: a systematic literature review. Suppot Care Cancer. 2012;20(12):3055–64.CrossRef
13.
go back to reference Sadja J, Mills PJ. Effects of yoga interventions on fatigue in cancer patients and survivors: a systematic review of randomized controlled trials. Explore. 2013;9(4):232–43.CrossRef Sadja J, Mills PJ. Effects of yoga interventions on fatigue in cancer patients and survivors: a systematic review of randomized controlled trials. Explore. 2013;9(4):232–43.CrossRef
14.
go back to reference Fouladbakhsh JM, Stommel M. Gender, symptom experience, and use of complementary and alternative medicine practices among cancer survivors in the US cancer population. Oncol Nurs Forum. 2010;37(1).CrossRef Fouladbakhsh JM, Stommel M. Gender, symptom experience, and use of complementary and alternative medicine practices among cancer survivors in the US cancer population. Oncol Nurs Forum. 2010;37(1).CrossRef
15.
go back to reference Gowin K, Millstine D, Kosiorek H, et al. The SIMM study: survey of integrative medicine in myeloproliferative neoplasms. Haematologica. 2017;102:192.CrossRef Gowin K, Millstine D, Kosiorek H, et al. The SIMM study: survey of integrative medicine in myeloproliferative neoplasms. Haematologica. 2017;102:192.CrossRef
16.
go back to reference Huberty J, Eckert R, Gowin K, et al. Feasibility study of online-streamed yoga for symptom management in patients with myeloproliferative neoplasms. Haematologica. 2017; ePub ahead of print. Huberty J, Eckert R, Gowin K, et al. Feasibility study of online-streamed yoga for symptom management in patients with myeloproliferative neoplasms. Haematologica. 2017; ePub ahead of print.
17.
go back to reference Geyer H, Scherber R, Kosiorek H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncology. 2015;34(2):151–9.CrossRef Geyer H, Scherber R, Kosiorek H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncology. 2015;34(2):151–9.CrossRef
19.
go back to reference Bowen DJ, Kreuter M, Spring B, et al. How we design feasibility studies. Am J Prev Med. 2009;36(5):452–7.CrossRef Bowen DJ, Kreuter M, Spring B, et al. How we design feasibility studies. Am J Prev Med. 2009;36(5):452–7.CrossRef
20.
go back to reference Flynn KE, Lin L, Cyranowski JM, et al. Development of the NIH PROMIS® sexual function and satisfaction measures in patients with cancer. J Sex Med. 2013;10(S1):43–52.CrossRef Flynn KE, Lin L, Cyranowski JM, et al. Development of the NIH PROMIS® sexual function and satisfaction measures in patients with cancer. J Sex Med. 2013;10(S1):43–52.CrossRef
21.
go back to reference Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873–80.CrossRef Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873–80.CrossRef
22.
go back to reference Quach CW, Langer MM, Chen RC, et al. Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study. Qual Life Res. 2016:1–13. Quach CW, Langer MM, Chen RC, et al. Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study. Qual Life Res. 2016:1–13.
23.
go back to reference Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six patient-reported outcomes measurement information system-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64(5):507–16.CrossRef Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six patient-reported outcomes measurement information system-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64(5):507–16.CrossRef
24.
go back to reference Sullivan GM, Feinn R. Using effect size—or why the P value is not enough. J Grad Med Educ. 2012;4(3):279–82.CrossRef Sullivan GM, Feinn R. Using effect size—or why the P value is not enough. J Grad Med Educ. 2012;4(3):279–82.CrossRef
25.
go back to reference Waart H, Harten WH, Buffart LM, Sonke GS, Stuiver MM, Aaronson NK. Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer? Psychooncology. 2015. Waart H, Harten WH, Buffart LM, Sonke GS, Stuiver MM, Aaronson NK. Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer? Psychooncology. 2015.
26.
go back to reference Adams SA, Matthews CE, Ebbeling CB, et al. The effect of social desirability and social approval on self-reports of physical activity. Am J Epidemiol. 2005;161(4):389–98.CrossRef Adams SA, Matthews CE, Ebbeling CB, et al. The effect of social desirability and social approval on self-reports of physical activity. Am J Epidemiol. 2005;161(4):389–98.CrossRef
27.
go back to reference Brenner PS, DeLamater JD. Social desirability bias in self-reports of physical activity: is an exercise identity the culprit? Soc Indic Res. 2014;117(2):489–504.CrossRef Brenner PS, DeLamater JD. Social desirability bias in self-reports of physical activity: is an exercise identity the culprit? Soc Indic Res. 2014;117(2):489–504.CrossRef
28.
go back to reference Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M, Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10(1):1.CrossRef Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M, Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10(1):1.CrossRef
29.
go back to reference Randell RL, Gulati AS, Cook SF, et al. Collecting biospecimens from an internet-based prospective cohort study of inflammatory bowel disease (CCFA partners): a feasibility study. JMIR Res Protocol. 2016;5(1):e3.CrossRef Randell RL, Gulati AS, Cook SF, et al. Collecting biospecimens from an internet-based prospective cohort study of inflammatory bowel disease (CCFA partners): a feasibility study. JMIR Res Protocol. 2016;5(1):e3.CrossRef
30.
go back to reference Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediat Inflamm. 2015. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediat Inflamm. 2015.
31.
go back to reference Bower JE, Greendale G, Crosswell AD, et al. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. Psychoneuroendocrinology. 2014;43:20–9.CrossRef Bower JE, Greendale G, Crosswell AD, et al. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. Psychoneuroendocrinology. 2014;43:20–9.CrossRef
32.
go back to reference Kiecolt-Glaser JK, Bennett JM, Andridge R, et al. Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32(10):1040–9.CrossRef Kiecolt-Glaser JK, Bennett JM, Andridge R, et al. Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32(10):1040–9.CrossRef
33.
go back to reference Price GL, Davis KL, Karve S, Pohl G, Walgren RA. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 2014;9(3):e9029.CrossRef Price GL, Davis KL, Karve S, Pohl G, Walgren RA. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 2014;9(3):e9029.CrossRef
34.
go back to reference Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: north central cancer treatment group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673–9.CrossRef Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: north central cancer treatment group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673–9.CrossRef
35.
go back to reference Barton DL, Soori GS, Bauer BA, et al. Pilot study of panax quinquefolius (american ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010;18(2):179–87.CrossRef Barton DL, Soori GS, Bauer BA, et al. Pilot study of panax quinquefolius (american ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010;18(2):179–87.CrossRef
36.
go back to reference Barton DL, Liu H, Dakhil SR, et al. Wisconsin ginseng (panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.CrossRef Barton DL, Liu H, Dakhil SR, et al. Wisconsin ginseng (panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.CrossRef
37.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRef
38.
go back to reference Yue Z, Li C, Weilin Q, Bin W. Application of the health belief model to improve the understanding of antihypertensive medication adherence among chinese patients. Patient Educ Couns. 2015;98(5):669–73.CrossRef Yue Z, Li C, Weilin Q, Bin W. Application of the health belief model to improve the understanding of antihypertensive medication adherence among chinese patients. Patient Educ Couns. 2015;98(5):669–73.CrossRef
Metadata
Title
Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research
Authors
Jennifer Huberty
Ryan Eckert
Amylou Dueck
Heidi Kosiorek
Linda Larkey
Krisstina Gowin
Ruben Mesa
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2530-8

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue